ReachMD julkinen
[search 0]
Lisää
Download the App!
show episodes
 
Artwork

1
ReachMD CME

ReachMD

icon
Unsubscribe
icon
Unsubscribe
Päivittäin
 
Your professional development is critical to the care of your patients. Stay on top of the latest treatments and information with ReachMD's CME activities. Our topics span cardiology, diabetes, oncology, cardiology, women's health and more. And our CME library is continuously growing, every quarter.
  continue reading
 
Loading …
show series
 
CME credits: 0.25 Valid until: 16-04-2026 Claim your CME credit at https://reachmd.com/programs/cme/first-line-chemotherapy-options-in-metastatic-pdac/33135/ Pancreatic ductal adenocarcinoma, also known as PDAC, is a lethal disease that is usually diagnosed at an advanced stage with an extremely poor prognosis. Advancements in treatment regimens ha…
  continue reading
 
CME credits: 0.25 Valid until: 16-04-2026 Claim your CME credit at https://reachmd.com/programs/cme/second-line-chemotherapy-options-in-metastatic-pdac/33136/ Pancreatic ductal adenocarcinoma, also known as PDAC, is a lethal disease that is usually diagnosed at an advanced stage with an extremely poor prognosis. Advancements in treatment regimens h…
  continue reading
 
CME credits: 1.00 Valid until: 02-04-2026 Claim your CME credit at https://reachmd.com/programs/cme/new-frontiers-in-mg-how-fcrn-antagonists-are-changing-mg-therapy/32731/ While traditional therapies for generalized myasthenia gravis (gMG) have proven beneficial in the short term, new treatment options with fewer debilitating side effects and longe…
  continue reading
 
CME credits: 1.00 Valid until: 02-04-2026 Claim your CME credit at https://reachmd.com/programs/cme/a-scientific-look-at-fcrn-antagonists-mechanisms-of-action-explained/32730/ While traditional therapies for generalized myasthenia gravis (gMG) have proven beneficial in the short term, new treatment options with fewer debilitating side effects and l…
  continue reading
 
CME credits: 1.00 Valid until: 02-04-2026 Claim your CME credit at https://reachmd.com/programs/cme/managing-side-effects-in-fcrn-therapy-best-practices-for-gmg/32732/ While traditional therapies for generalized myasthenia gravis (gMG) have proven beneficial in the short term, new treatment options with fewer debilitating side effects and longer-te…
  continue reading
 
CME credits: 1.00 Valid until: 02-04-2026 Claim your CME credit at https://reachmd.com/programs/cme/diagnostic-advances-in-gmg-effective-tools-and-techniques/32727/ While traditional therapies for generalized myasthenia gravis (gMG) have proven beneficial in the short term, new treatment options with fewer debilitating side effects and longer-term …
  continue reading
 
CME credits: 1.00 Valid until: 02-04-2026 Claim your CME credit at https://reachmd.com/programs/cme/precision-medicine-for-gmg-tailoring-treatments-based-on-patient-profiles/32735/ While traditional therapies for generalized myasthenia gravis (gMG) have proven beneficial in the short term, new treatment options with fewer debilitating side effects …
  continue reading
 
CME credits: 1.00 Valid until: 02-04-2026 Claim your CME credit at https://reachmd.com/programs/cme/autoantibodies-explained-anti-achr-anti-musk-and-their-diagnostic-role/32728/ While traditional therapies for generalized myasthenia gravis (gMG) have proven beneficial in the short term, new treatment options with fewer debilitating side effects and…
  continue reading
 
CME credits: 1.00 Valid until: 02-04-2026 Claim your CME credit at https://reachmd.com/programs/cme/preventing-myasthenic-crisis-early-signs-and-critical-interventions/32734/ While traditional therapies for generalized myasthenia gravis (gMG) have proven beneficial in the short term, new treatment options with fewer debilitating side effects and lo…
  continue reading
 
CME credits: 1.00 Valid until: 02-04-2026 Claim your CME credit at https://reachmd.com/programs/cme/ocular-to-generalized-mg-how-and-why-the-disease-evolves/32733/ While traditional therapies for generalized myasthenia gravis (gMG) have proven beneficial in the short term, new treatment options with fewer debilitating side effects and longer-term b…
  continue reading
 
CME credits: 1.00 Valid until: 02-04-2026 Claim your CME credit at https://reachmd.com/programs/cme/traditional-mg-treatments-balancing-benefits-risks-and-side-effect-management/32729/ While traditional therapies for generalized myasthenia gravis (gMG) have proven beneficial in the short term, new treatment options with fewer debilitating side effe…
  continue reading
 
CME credits: 1.00 Valid until: 02-04-2026 Claim your CME credit at https://reachmd.com/programs/cme/living-with-gmg-navigating-personal-professional-and-mental-health-challenges/32726/ While traditional therapies for generalized myasthenia gravis (gMG) have proven beneficial in the short term, new treatment options with fewer debilitating side effe…
  continue reading
 
CME credits: 1.00 Valid until: 21-11-2026 Claim your CME credit at https://reachmd.com/programs/cme/DefiningtheStandardofCareandOptimalSequencinginBRAFMutantmCRcSecondLineandBeyond/32944/ In this series, Dr. Fortunato Ciardiello and Dr. Jenny Seligmann review the management of metastatic colorectal cancer (mCRC), with a focus on timing and methodol…
  continue reading
 
CME credits: 1.00 Valid until: 21-11-2026 Claim your CME credit at https://reachmd.com/programs/cme/CaseConsultAdverseEffectMonitoringManagementandMitigationDuringTargetedTherapyforBRAFMutantmCRc/33134/ In this series, Dr. Fortunato Ciardiello and Dr. Jenny Seligmann review the management of metastatic colorectal cancer (mCRC), with a focus on timi…
  continue reading
 
CME credits: 0.75 Valid until: 31-03-2026 Claim your CME credit at https://reachmd.com/programs/cme/distinguishing-between-anti-pd-1-agents-in-escc-combination-therapies/29790/ This online CME activity focuses on the first-line treatment of advanced or metastatic esophageal squamous cell carcinoma (ESCC) with the addition of an immune checkpoint in…
  continue reading
 
CME credits: 0.75 Valid until: 31-03-2026 Claim your CME credit at https://reachmd.com/programs/cme/effective-monitoring-and-management-of-adverse-effects-in-metastatic-escc/29792/ This online CME activity focuses on the first-line treatment of advanced or metastatic esophageal squamous cell carcinoma (ESCC) with the addition of an immune checkpoin…
  continue reading
 
CME credits: 0.75 Valid until: 31-03-2026 Claim your CME credit at https://reachmd.com/programs/cme/the-importance-of-pd-l1-testing-shaping-the-future-of-treatment-in-escc/29791/ This online CME activity focuses on the first-line treatment of advanced or metastatic esophageal squamous cell carcinoma (ESCC) with the addition of an immune checkpoint …
  continue reading
 
CME credits: 0.75 Valid until: 31-03-2026 Claim your CME credit at https://reachmd.com/programs/cme/the-impact-of-first-line-treatment-on-subsequent-treatment-options-for-metastatic-escc/33031/ This online CME activity focuses on the first-line treatment of advanced or metastatic esophageal squamous cell carcinoma (ESCC) with the addition of an imm…
  continue reading
 
CME credits: 1.00 Valid until: 21-11-2026 Claim your CME credit at https://reachmd.com/programs/cme/ProactiveAdverseEffectManagementinmCRCImprovingTolerabilitytoOptimizePatientOutcomes/32945/ In this series, Dr. Fortunato Ciardiello and Dr. Jenny Seligmann review the management of metastatic colorectal cancer (mCRC), with a focus on timing and meth…
  continue reading
 
CME credits: 0.75 Valid until: 31-03-2026 Claim your CME credit at https://reachmd.com/programs/cme/tailoring-first-line-regimens-patient-centric-selection-in-metastatic-escc/33030/ This online CME activity focuses on the first-line treatment of advanced or metastatic esophageal squamous cell carcinoma (ESCC) with the addition of an immune checkpoi…
  continue reading
 
CME credits: 1.00 Valid until: 21-11-2026 Claim your CME credit at https://reachmd.com/programs/cme/MutationalTestinginmCRcMethodsandDataDrivingTreatmentSelection/32942/ In this series, Dr. Fortunato Ciardiello and Dr. Jenny Seligmann review the management of metastatic colorectal cancer (mCRC), with a focus on timing and methodology of molecular t…
  continue reading
 
CME credits: 0.75 Valid until: 31-03-2026 Claim your CME credit at https://reachmd.com/programs/cme/strategies-for-navigating-first-line-treatment-selection-in-metastatic-escc/33029/ This online CME activity focuses on the first-line treatment of advanced or metastatic esophageal squamous cell carcinoma (ESCC) with the addition of an immune checkpo…
  continue reading
 
CME credits: 1.00 Valid until: 21-11-2026 Claim your CME credit at https://reachmd.com/programs/cme/from-guidelines-to-practice-first-line-treatment-choices-in-mcrc/32943/ In this series, Dr. Fortunato Ciardiello and Dr. Jenny Seligmann review the management of metastatic colorectal cancer (mCRC), with a focus on timing and methodology of molecular…
  continue reading
 
CME credits: 0.75 Valid until: 31-03-2026 Claim your CME credit at https://reachmd.com/programs/cme/ici-combination-regimens-for-first-line-treatment-of-metastatic-escc/33028/ This online CME activity focuses on the first-line treatment of advanced or metastatic esophageal squamous cell carcinoma (ESCC) with the addition of an immune checkpoint inh…
  continue reading
 
CME credits: 0.50 Valid until: 26-03-2026 Claim your CME credit at https://reachmd.com/programs/cme/antibody-drug-conjugates-in-bladder-cancer-guideline-updates-and-adverse-event-management/29174/ New understanding of molecular targets has helped transform invasive bladder cancer treatment, and guidelines now recommend chemotherapy-free immunothera…
  continue reading
 
CME credits: 1.00 Valid until: 14-03-2026 Claim your CME credit at https://reachmd.com/programs/cme/collaborative-insights-to-solve-the-puzzle-of-bladder-cancer/30062/ This online educational activity, derived from a live satellite symposium at ASCO GU 2025, explores innovative strategies for personalized care in bladder cancer. Participants will g…
  continue reading
 
CME credits: 1.50 Valid until: 14-03-2026 Claim your CME credit at https://reachmd.com/programs/cme/factoring-solutions-to-the-management-of-stroke-care-in-the-settings-of-secondary-prevention-and-af/29099/ Despite significant efforts to prevent stroke in patients, there remains an unmet need among providers regarding the optimization and benefit-r…
  continue reading
 
CME credits: 1.00 Valid until: 13-03-2026 Claim your CME credit at https://reachmd.com/programs/cme/personalizing-care-within-the-rcc-treatment-paradigm/29528/ This online educational activity, derived from a live satellite symposium at ASCO GU 2025, explores the latest advances in risk stratification and evidence-based approaches for managing adva…
  continue reading
 
CME credits: 0.50 Valid until: 28-02-2026 Claim your CME credit at https://reachmd.com/programs/cme/is-it-nonresponsiveprogressive-ism/32714/ The identification of KIT D816V mutation as a key driver for the expansion and accumulation of neoplastic mast cells in systemic mastocytosis (SM) has significantly improved the diagnosis, subclassification, …
  continue reading
 
CME credits: 0.25 Valid until: 28-02-2026 Claim your CME credit at https://reachmd.com/programs/cme/advancing-multidisciplinary-care-in-tgct-integrating-systemic-therapies-and-surgical-approaches/29871/ In this activity, a medical oncologist and orthopedic surgeon discuss evidence-based surgical and systemic therapy approaches for the treatment of …
  continue reading
 
CME credits: 0.50 Valid until: 28-02-2026 Claim your CME credit at https://reachmd.com/programs/cme/diagnosis-and-treatment-of-systemic-mastocytosis-with-an-associated-hematologic-neoplasm/32715/ The identification of KIT D816V mutation as a key driver for the expansion and accumulation of neoplastic mast cells in systemic mastocytosis (SM) has sig…
  continue reading
 
CME credits: 0.50 Valid until: 28-02-2026 Claim your CME credit at https://reachmd.com/programs/cme/accurate-diagnosis-and-management-of-hereditary-alpha-tryptasemia/32716/ The identification of KIT D816V mutation as a key driver for the expansion and accumulation of neoplastic mast cells in systemic mastocytosis (SM) has significantly improved the…
  continue reading
 
CME credits: 0.50 Valid until: 28-02-2026 Claim your CME credit at https://reachmd.com/programs/cme/differential-diagnosis-of-indolent-systemic-mastocytosis/32713/ The identification of KIT D816V mutation as a key driver for the expansion and accumulation of neoplastic mast cells in systemic mastocytosis (SM) has significantly improved the diagnosi…
  continue reading
 
CME credits: 0.50 Valid until: 21-02-2026 Claim your CME credit at https://reachmd.com/programs/cme/exploring-new-and-emerging-treatments-in-muscle-invasive-bladder-cancer/32676/ New understanding of molecular targets has helped transform invasive bladder cancer treatment, and guidelines now recommend chemotherapy-free immunotherapy as first-line t…
  continue reading
 
CME credits: 0.50 Valid until: 21-02-2026 Claim your CME credit at https://reachmd.com/programs/cme/reviewing-the-latest-bladder-cancer-practice-guidelines/32675/ New understanding of molecular targets has helped transform invasive bladder cancer treatment, and guidelines now recommend chemotherapy-free immunotherapy as first-line treatment for met…
  continue reading
 
CME credits: 0.50 Valid until: 21-02-2026 Claim your CME credit at https://reachmd.com/programs/cme/patient-perspectives-on-bladder-cancer/32677/ New understanding of molecular targets has helped transform invasive bladder cancer treatment, and guidelines now recommend chemotherapy-free immunotherapy as first-line treatment for metastatic bladder c…
  continue reading
 
CME credits: 0.75 Valid until: 14-02-2026 Claim your CME credit at https://reachmd.com/programs/cme/dont-miss-it-rapid-accurate-aav-diagnosis/32348/ Blood vessel inflammation that occurs with anti-neutrophil cytoplasmic autoantibody (ANCA)-associated vasculitis – or AAV – often results in damage that can lead to multi-organ involvement. This makes …
  continue reading
 
CME credits: 0.75 Valid until: 14-02-2026 Claim your CME credit at https://reachmd.com/programs/cme/managing-patients-with-aav-in-the-rheumatology-clinic/32353/ Blood vessel inflammation that occurs with anti-neutrophil cytoplasmic autoantibody (ANCA)-associated vasculitis – or AAV – often results in damage that can lead to multi-organ involvement.…
  continue reading
 
CME credits: 1.00 Valid until: 14-02-2026 Claim your CME credit at https://reachmd.com/programs/cme/how-do-we-translate-real-world-af-data-into-everyday-clinical-practice/32299/ The effective management of atrial fibrillation (AF) remains a high priority for many clinicians worldwide because a significant number of people globally who are living wi…
  continue reading
 
CME credits: 0.75 Valid until: 14-02-2026 Claim your CME credit at https://reachmd.com/programs/cme/tailoring-treatment-for-optimal-outcomes-in-patients-with-aav/32351/ Blood vessel inflammation that occurs with anti-neutrophil cytoplasmic autoantibody (ANCA)-associated vasculitis – or AAV – often results in damage that can lead to multi-organ invo…
  continue reading
 
CME credits: 1.00 Valid until: 14-02-2026 Claim your CME credit at https://reachmd.com/programs/cme/how-do-we-translate-real-world-vte-data-into-everyday-clinical-practice-for-ongoing-anticoagulation/32303/ The effective management of atrial fibrillation (AF) remains a high priority for many clinicians worldwide because a significant number of peop…
  continue reading
 
CME credits: 1.00 Valid until: 14-02-2026 Claim your CME credit at https://reachmd.com/programs/cme/patient-case-study-obesity-and-vte/32305/ The effective management of atrial fibrillation (AF) remains a high priority for many clinicians worldwide because a significant number of people globally who are living with AF are at risk of developing veno…
  continue reading
 
CME credits: 1.00 Valid until: 14-02-2026 Claim your CME credit at https://reachmd.com/programs/cme/patient-case-study-obesity/32301/ The effective management of atrial fibrillation (AF) remains a high priority for many clinicians worldwide because a significant number of people globally who are living with AF are at risk of developing venous throm…
  continue reading
 
CME credits: 0.75 Valid until: 14-02-2026 Claim your CME credit at https://reachmd.com/programs/cme/implementing-the-soc-induction-therapies-in-aav/32349/ Blood vessel inflammation that occurs with anti-neutrophil cytoplasmic autoantibody (ANCA)-associated vasculitis – or AAV – often results in damage that can lead to multi-organ involvement. This …
  continue reading
 
CME credits: 0.75 Valid until: 14-02-2026 Claim your CME credit at https://reachmd.com/programs/cme/elevating-care-for-patients-with-severe-renal-disease-in-aav/32352/ Blood vessel inflammation that occurs with anti-neutrophil cytoplasmic autoantibody (ANCA)-associated vasculitis – or AAV – often results in damage that can lead to multi-organ invol…
  continue reading
 
CME credits: 1.00 Valid until: 14-02-2026 Claim your CME credit at https://reachmd.com/programs/cme/patient-case-study-elderly/32300/ The effective management of atrial fibrillation (AF) remains a high priority for many clinicians worldwide because a significant number of people globally who are living with AF are at risk of developing venous throm…
  continue reading
 
CME credits: 0.75 Valid until: 14-02-2026 Claim your CME credit at https://reachmd.com/programs/cme/optimizing-aav-outcomes-maintenance-therapies/32350/ Blood vessel inflammation that occurs with anti-neutrophil cytoplasmic autoantibody (ANCA)-associated vasculitis – or AAV – often results in damage that can lead to multi-organ involvement. This ma…
  continue reading
 
CME credits: 1.00 Valid until: 14-02-2026 Claim your CME credit at https://reachmd.com/programs/cme/trade-off-ischemicthrombotic-vs-bleeding/32297/ The effective management of atrial fibrillation (AF) remains a high priority for many clinicians worldwide because a significant number of people globally who are living with AF are at risk of developin…
  continue reading
 
CME credits: 1.00 Valid until: 14-02-2026 Claim your CME credit at https://reachmd.com/programs/cme/setting-the-stage-of-real-world-data-vs-rct/32296/ The effective management of atrial fibrillation (AF) remains a high priority for many clinicians worldwide because a significant number of people globally who are living with AF are at risk of develo…
  continue reading
 
CME credits: 1.00 Valid until: 14-02-2026 Claim your CME credit at https://reachmd.com/programs/cme/implications-associated-with-integrating-both-real-world-data-and-clinical-trial-data-into-clinical-practice-vte-considerations/32302/ The effective management of atrial fibrillation (AF) remains a high priority for many clinicians worldwide because …
  continue reading
 
Loading …

Pikakäyttöopas

Kuuntele tämä ohjelma tutkiessasi
Toista